Inspira 'to Report Primary Results for Core Blood Oxygenation Tech Within Days'

 

• The major milestone refers to Inspira's proprietary technology to oxygenate blood for the INSPIRA™ ART (Gen 2). This patented tech is considered by Inspira to be a game-changer and also aims to replace technologies used today by current medical device companies.
• Anticipated U.S. Food and Drug Administration (FDA) Clearance for INSPIRA™ ART100 (Gen 1) in the first half of 2024, to address the $1.16 Billion perfusion systems market.

https://www.biospace.com/article/releases/inspira-announces-plans-to-report-the-primary-results-for-a-core-blood-oxygenation-technology-within-days/